key: cord-0915748-35knp1oh authors: Dyavar, Shetty Ravi; Singh, Rahul; Emani, Rohini; Pawar, Ganesh P.; Chaudhari, Vinod D.; Podany, Anthony T.; Avedissian, Sean; Fletcher, Courtney V.; Salunke, Deepak B. title: Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic options date: 2021-06-10 journal: Biomed Pharmacother DOI: 10.1016/j.biopha.2021.111794 sha: e8497d11895037ab2a52a46a0be134507bba44de doc_id: 915748 cord_uid: 35knp1oh Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) is the causative agent of Corona Virus Disease 2019 (COVID-19). Lower production of type I and III interferons and higher levels of inflammatory mediators upon SARS-CoV2 infection contribute to COVID-19 pathogenesis. Optimal interferon production and controlled inflammation are essential to limit COVID-19 pathogenesis. However, the aggravated inflammatory response observed in COVID-19 patients causes severe damage to the host and frequently advances to acute respiratory distress syndrome (ARDS). Toll-like receptor 7 and 8 (TLR7/8) signaling pathways play a central role in regulating induction of interferons (IFNs) and inflammatory mediators in dendritic cells. Controlled inflammation is possible through regulation of TLR mediated response without influencing interferon production and may reduce COVID-19 pathogenesis. This review focuses on inflammatory mediators contribute to pathogenic effects and the role of TLR pathways in the induction of interferon and inflammatory mediators and their contribution to COVID-19 pathogenesis. We conclude that potential TLR7/8 agonists inducing antiviral interferon response and control inflammation are important therapeutic options to effectively eliminate SARS-CoV2 induced pathogenesis. Ongoing and future studies may provide additional evidence on their safety and efficacy to treat COVID-19 pathogenesis. In humans, the spike protein of SARS-CoV2 interacts with angiotensin-converting enzyme 2 (ACE2) receptors expressed on the surface of epithelial cells present in the lung, gut, and other organs, thereby establishing infection 5 . COVID-19 is symptomatically characterized by high fever, cough, general malaise, and a pathology associated with immediate and robust production of pro-inflammatory cytokine mediators in blood, lung, gut, and other tissue compartments [6] [7] . Symptomatic patients may advance to acute respiratory distress syndrome (ARDS) displaying pneumonitis, shock, organ failure, and even death [7] [8] [9] [10] . Currently, a comprehensive understanding on the role of inflammatory mediators released into the plasma and expressed in peripheral blood mononuclear cells (PBMCs) and bronchoalveolar lavage fluid (BALF) is unavailable. Potential therapies to induce vital type I interferon (IFN) responses and control inflammation and their association with the regulation of TLR pathways are still under investigation. This review focuses on i) inflammatory mediators observed in plasma, PBMCs and BALF samples of J o u r n a l P r e -p r o o f SARS-CoV2 infected preclinical models and patients; ii) regulation of type I IFNs during coronaviral infections; iii) current and potential therapies to limit SARS-CoV2 replication and pathogenesis; iv) toll-like receptors (TLRs) mediated antiviral and inflammatory responses during coronaviral infection and v) potential TLR7/8 agonists as potential therapeutics to treat coronaviral infections. Inflammation is the primary response initiated by immune cells in the body of pathogen infected individuals to limit replication of the pathogen and tissue damage. Robust and high level of cytokine and chemokine production following infection, which termed as cytokine storm and may cause severe tissue damage and was observed in SARS, MERS and SARS-CoV2 infections [11] [12] [13] . Cytokine storm contributes to progressive lung tissue damage and the development of often fatal ARDS 14 . Over 30 different cytokine levels are altered following SARS-CoV2 infection in the plasma of COVID-19 patients 6, 13, 15 . Several of the pro-and antiinflammatory cytokines are known to increase in plasma SARS-CoV2 RNA copies, disease severity and ARDS (Table 1) . Preclinical and clinical studies have provided several lines of evidence on pro-and anti-inflammatory cytokines released into peripheral blood of corona virus infected animal models and patients 6, 13, 15 increase in levels of IL-1β, interleukin 1 receptor antagonist (IL1-RA), IL-7, IL-8, IL-9, IL-10, FGF, G-CSF, GM-CSF, IFNγ, IP10, MCP1, MIP1A, MIP1B, PDGF, TNFα, and VEGF as compared with healthy volunteers 6 . In the same study, comparison between patients admitted to ICU showed higher IL-2, IL-7, IL-10, G-CSF, IP10 Further, CCL2 and CCL8 22-24 expression attracts monocytes and macrophages. In addition, CXCL8 expression attracts neutrophils 17, 22, 25 in large numbers to BALF. Migration of these cells to lung tissue may potentially can drive profound inflammation and advance to lung pathology 21 . In severe COVID-19 cases, CD4, CD8, NK and plasmacytoid DCs were reduced, while activated (HLA-DR+ CD38+ve) CD4, CD8, NK cell numbers were increased in blood demonstrating hyper immune activation [26] [27] [28] (Table 1) . Pro-inflammatory microenvironment maintained by heightened proinflammatory factors, extremely low levers of anti-inflammatory factors hyperimmune activation may cause lung injury in severe SARS-CoV2 infected persons 29 . This hypothesis was further supported with the evidence obtained on increased bacterial products (lipopolysaccharides) observed in the plasma of severe SARS-CoV2 infected persons who have advanced to ARDS 19 . Hyperimmune activation in COVID-19 patients was correlated with increased plasma IL-6, TNF, MCP-3, EN-RAGE, TNFSF14, and OSM levels 19 . Higher numbers of HLADR+CD38+ve CD4, CD8 and NK cells and increased quantity of microbial products in blood were also observed in HIV infected patients which contribute to hyperimmune activation 30-32 . Similar findings were observed in HIV infected persons who have showed higher non-specific activation of CD4 and CD8 T cells and translocation of microbes from the gut to peripheral blood compartments advances the disease to AIDS 30-32 . Previous reports showed that reduced hyperimmune activation could control HIV infection and improve T cell function 32-33 . Though these pathogenic mechanisms were similar between HIV and COVID-19, an interesting difference was noticed on regulation of type I interferon response. Type I IFN (IFN-α/β) induction is a central event in innate immune response initiated as a part of the defense against SARS-CoV2 infection. Type I IFNs are produced by pDCs, monocytes, macrophages 35-37 . Type I IFNs enhance DC maturation, regulate T cell growth properties and promote NK and CD8 T cell-induced cytotoxicity 38 . In contrast to initial reports, increasing evidence suggests that patients with severe COVID-19 have a delayed and blunted type I IFN response [39] [40] . In SARS-CoV2 J o u r n a l P r e -p r o o f infected preclinical NHBE and ferret models and clinically symptomatic persons, low plasma IFN-I/-III levels have been observed. This finding is significant as the lack of host associated immune defenses have been shown to increase disease severity 21, 26 . In contrast, Zhou et al. showed higher amounts of interferon stimulatory genes (ISGs) in BALF 40 . Though additional evidence is needed, the existing results have demonstrated that compartmentalized IFN responses are observed in COVID-19 patients. This observation can be further explained by the increased number of IFN producing pDCs, which may have migrated from peripheral blood to lung and gut tissue due to induction of migratory molecules such as α4β7 [41] [42] [43] . T cells and pDCs migrate to gut tissues with their ability to bind α4β7 with MadCAM1 receptor and may cause inflammation [41] [42] [43] . Aggravated inflammation due to increased production of cytokines, chemokine mediators and hyper activity of immune cells including pDCs in lung tissue may cause acute respiratory distress syndrome (ARDS), and sustained inflammation may lead to multiple organ failure and ultimately death in COVID-19 patients 44 . Strategies to control inflammation may reduce disease severity and thereby increase the survival rate of COVID-19 patients. Coronaviruses have developed unique immune evasion strategies to escape hostmediated antiviral innate immune response 45 thereby preventing IFN induction 46 . SARS-CoV associated non-structural proteins 1 (nsp1), nsp3, N proteins were known to prevent IFN responses 47 . In addition, SARS-CoV associated papain-like protease (PLPro) inhibits TLR7 induced type I IFN-α/β production through suppression of IRF-3, Nuclear Factor-κB (NF-κB) and Activator Protein-1 (AP-1) in human promonocytes 48 States. SARS-CoV2 infected patients who received remdesivir therapy achieved clinical endpoint recovery (e.g., hospital discharge) at a faster rate as compared to placebo controls [52] [53] . Following administration of remdesivir, penetration into human cells generates the antivirally active GS-441524 monophosphate metabolite analogous to adenosine nucleoside triphosphate. This metabolite shows antiviral activity through inhibition of RDRP activity and thereby limits viral replication 53 . In critically ill COVID-19 patients admitted to the ICU, more than a 44% mortality rate was observed even after receiving remdesivir therapy 53 . In this study, 35 patients J o u r n a l P r e -p r o o f were enrolled, including 18 in ICU and 17 in infectious disease ward (IDW). A ten day remdesivir course was completed by 22 (63%) of these patients 53 . On day 28, 14 (82.3 %) of 17 patients in IDW were discharged, two were still receiving care in the hospital and one (5.9%) died. In ICU, 6 (33.3%) were discharged following their recovery, three (16.7%) were mechanically ventilated and one (5.6%) was improved but still hospitalized. Whereas, 8 patients (44%) died 53 . Hypertransaminasemia 40 . In another study, IFNβ-1a treatment in 44 COVID-19 patients along with hydroxychloroquine plus lopinavir/ritonavir or atazanavir/ritonavir showed some benefit with a 23.1% increase in hospital discharge rate and 24.6% reduction in mortality rate as compared with patients on standard drug regimen 58 . Collectively data generated from these studies have demonstrated that the use of interferons as a promising therapeutic approach to treat COVID-19 patients. In a group of low-risk (2415) healthy persons, administration of 2-3 nasal drops of recombinant human IFNα (rhIFNα) for four times a day, and in a group of high-risk (529) healthy persons, administration of hrIFNα combined with thymosin-α1 (1.6 mg, hypodermic injection, once a week) for 28 days protected from SARS-CoV2 infection 59 . These studies have demonstrated that IFNs serve as potential prophylactic agents to treat corona viral infections and provided information on the safety and targeted period that needs to be carefully monitored before recommending them as standard therapies. Persistent IFN response may stimulate many ISGs, which can induce antiviral state in responsive cells but may also induce apoptosis and fibrosis and thereby cause immunopathology. Timing and dose adjustment while using recombinant IFNs may reduce side effects and control SARS-CoV2 infection and COVID-19 pathogenesis 40 . In summary, to minimize COVID-19 morbidity and mortality, there is still a significant need to develop effective therapies to limit viral infection and dampen cytokinemediated inflammatory response [48] [49] . Future studies may focus on developing prophylactic and treatment strategies to prevent SARS-CoV2 infection with small molecules and IFNs while reducing lung inflammation. A large body of evidence suggests that cytokine mediated inflammation play a major role in COVID-19 pathogenesis 6-7 . IL-6 was identified as a major regulator of SARS-CoV2 induced inflammation. Therefore, IL-6 antagonism was suggested as a novel therapy to treat critically ill COVID-19 patients with significantly elevated IL-6 levels [60] [61] . A study conducted in 134 ICU patients treated with tocilizumab, a humanized IL-6 receptor antagonistic monoclonal antibody, showed 10% lower mortality rate compared to those that did not receive therapy 62 . This study has demonstrated that reduced inflammation during SARS-CoV2 infection may recover patients and may decrease disease severity. However, in Roche's phase III COVACTA study of tocilizumab (Actemra/RoActemra), though time to discharge COVID-19 patients was eight days shorter in tocilizumab treated patients as compared with placebo, no difference was observed in their clinical status (https://www.roche.com/investors/updates/inv-update-2020-07-29.htm). Patient selection criteria should include higher IL-6 levels before recruitment; otherwise, these studies will generate results that are difficult to interpret and could fail to derive a therapeutic outcome. "The right patient, right timing, and right therapy" may work well to investigate novel therapies. In addition to IL-6, CRP, and serum ferritin may potentially predict reduced inflammation and serve as a vital biomarkers. These considerations based on biomarkers should be included in the selection criteria for patients to enroll in studies testing these novel therapies 63 agonists activate pDCs and monocytes, which induces a signaling cascade to produce IFN-α/β 50, 85 . In previous studies, TLR7 agonists were used as antiviral therapeutics to generate potent IFN response. For example, imiquimod, also called Aldara or R-837 is the first FDA approved topically active TLR7 agonist. Imiquimod activates pDCs to produce type I IFNs and was successfully used to treat human papillomavirus (HPV) infection-induced genital warts and is a therapeutic agent for basal cell carcinoma 7 . In a two randomized, double blind phase IIa studies, oral administration of resiquimod (0.02 mg/kg), a TLR7/8 agonist, twice a week for four weeks was well tolerated and induced interferon-alpha production and thereby reduced hepatitis C virus (HCV) 88 . Resiquimod may have anti-inflammatory effects, which is evident from "in vitro" experiments in which stimulation of monocytes derived from HIV-infected persons with resiquimod produced significantly less TNF-α than those derived from healthy controls providing the evidence on reducing the inflammation with TLR7/8 agonists 89 . TLR7 stimulation in the airways has the J o u r n a l P r e -p r o o f potential to reduce responses to aeroallergens by induction of type I IFNs. For example, GSK2245035, TLR7 agonist was tested in a randomized, double blind, placebo-controlled study (TL7116958) over two pollen seasons (n=42). Participants received eight single daily doses of low (20ng, n=14) or high (80ng, n=14) or placebo (n=14) for 8 weeks 83 . This study results showed that GSK2245035 was well tolerated and reduces allergic reactivity to nasal challenge for three weeks post The authors declare no competing interests. All together to Fight COVID-19 Public needs to prep for vaccine side effects Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19 Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies The Johnson & Johnson Vaccine for COVID-19 SARS-CoV-2 productively infects human gut enterocytes Lessons learned from SARS and MERS epidemic Surviving COVID-19: A disease tolerance perspective A Novel Coronavirus from Patients with Pneumonia in China An interferon-gamma-related cytokine storm in SARS patients MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 Immune Correlates of COVID-19 Control Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury In the eye of the COVID-19 cytokine storm Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China CoV-2: a storm is raging Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclassical monocytes Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors Signaling and the Induction of Type I Interferon Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19 Decoding type I and III interferon signalling during viral infection Dysregulation of type I interferon responses in COVID-19 Interferon-alpha2b Treatment for COVID-19 Leukocyte Trafficking to the Small Intestine and Colon Homing of immune cells: role in homeostasis and intestinal inflammation Dendritic Cell Accumulation in the Gut and Central Nervous System Is Differentially Dependent on alpha4 Integrins The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system Immunity and immunopathology to viruses: what decides the outcome? Early endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication Coronaviruses post-SARS: update on replication and pathogenesis SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6 Orf9b suppresses type I interferon responses by targeting TOM70 Novel drugs targeting Toll-like receptors for antiviral therapy Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status Remdesivir in adults with severe COVID-19: a randomised, doubleblind, placebo-controlled, multicentre trial Drug repurposing approach to fight COVID-19 Short-Term Dexamethasone in Sars-CoV-2 Patients Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial The effect of recombinant human interferon alpha nasal drops to prevent COVID-19 pneumonia for medical staff in an epidemic area IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy IL-6: Relevance for immunopathology of SARS-CoV-2 Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study Biomarkers associated with COVID-19 disease progression Mast cells and influenza a virus: association with allergic responses and beyond COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors Targeting human TLRs to combat COVID-19: A solution Elucidating the molecular Res Toll-like receptors in antiviral innate immunity Recent clinical trends in Toll-like receptor targeting therapeutics Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells Tolllike receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells Roles of TLR7 in activation of NF-kappaB signaling of keratinocytes by imiquimod The Toll for Trafficking: Toll-Like Receptor Species-specific recognition of single-stranded 8 Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 Structure-activity relationships in human Tolllike receptor 8-active 2,3-diamino-furo[2,3-c]pyridines The antiviral activity of Toll-like receptor 7 and 7/8 agonists Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod agonist, is an effective influenza vaccine adjuvant Substituted guanine ribonucleosides as B cell activators In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine) Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9 Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines Azithromycin distinctively modulates classical activation of human monocytes in vitro Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal Tables: Table 1 . Pro-and anti-inflammatory cytokines, chemokines and other mediators influencing SARS-CoV2 replication and ARDS.